A Second Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single and a Repeat Oral Dose of GSK256073A in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2012
At a glance
- Drugs GSK 256073 (Primary)
- Indications Dyslipidaemias; Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- 31 Aug 2018 Biomarkers information updated
- 24 Apr 2008 Status changed from recruiting to completed according to ClinicalTrials.gov.
- 16 Nov 2007 New trial record.